Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/37843
Title: HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors
Authors: CUPPENS, Kristof 
Baas, Paul
GEERDENS, Ellen 
Cruys, Bert
FROYEN, Guy 
Decoster, Lynn
THOMEER, Michiel 
MAES, Brigitte 
Issue Date: 2022
Publisher: 
Source: Lung cancer, 170
Abstract: Immune checkpoint inhibitors (ICIs) improved outcomes in non-small cell lung cancer (NSCLC) patients. We report the predictive utility of human leukocyte antigen class I (HLA-I) diversity and tumor mutational burden (TMB) by comprehensive next-generation sequencing.
Keywords: HED;HLA-I diversity;HLA-I evolutionary divergence;Non-small cell lung cancer;PD-1 immunotherapy;TSO500;Tumor mutational burden
Document URI: http://hdl.handle.net/1942/37843
ISSN: 0169-5002
e-ISSN: 1872-8332
DOI: 10.1016/j.lungcan.2022.05.019
ISI #: 000861749300001
Datasets of the publication: 10.1016/j.lungcan.2022.05.019
Rights: 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Category: A1
Type: Journal Contribution
Validations: ecoom 2023
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
1-s2.0-S0169500222004640-main.pdfPublished version3.68 MBAdobe PDFView/Open
Show full item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.